These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 27921577)

  • 1. The efficiency and safety of trastuzumab for advanced gastric and gastroesophageal cancer: a meta-analysis of five randomized controlled trials.
    Xiong B; Ma L; Huang W; Luo H; Zeng Y; Tian Y
    Growth Factors; 2016 Dec; 34(5-6):187-195. PubMed ID: 27921577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuation of trastuzumab beyond progression in HER2-positive advanced esophagogastric cancer: a meta-analysis.
    Ter Veer E; van den Ende T; Creemers A; de Waal L; van Oijen MGH; van Laarhoven HWM
    Acta Oncol; 2018 Dec; 57(12):1599-1604. PubMed ID: 30264641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical effectiveness of neoadjuvant chemotherapy in advanced gastric cancer: an updated meta-analysis of randomized controlled trials.
    Xiong B; Ma L; Cheng Y; Zhang C
    Eur J Surg Oncol; 2014 Oct; 40(10):1321-30. PubMed ID: 25239442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An updated meta-analysis of randomized controlled trial assessing the effect of neoadjuvant chemotherapy in advanced gastric cancer.
    Xiong BH; Cheng Y; Ma L; Zhang CQ
    Cancer Invest; 2014 Jul; 32(6):272-84. PubMed ID: 24800782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meta-analysis of six randomized control trials of chemotherapy plus anti-HER monoclonal antibody for advanced gastric and gastroesophageal cancer.
    Luo HQ; Han L; Jiang Y
    Asian Pac J Cancer Prev; 2014; 15(13):5343-8. PubMed ID: 25040999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Trastuzumab in combination with chemotherapy versus chemotherapy alone for first-line treatment of HER2-positive advanced gastric or gastroesophageal junction cancer: a Phase III, multi-center, randomized controlled trial, Chinese subreport].
    Shen L; Xu JM; Feng FY; Jiao SC; Wang LW; Li J; Guan ZZ; Qin SK; Wang JJ; Yu SY; Wang YJ; Jin YN; Tao M; Zheng LZ; Pan LX
    Zhonghua Zhong Liu Za Zhi; 2013 Apr; 35(4):295-300. PubMed ID: 23985260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II prospective study of the trastuzumab combined with 5-weekly S-1 and CDDP therapy for HER2-positive advanced gastric cancer.
    Kataoka H; Mori Y; Shimura T; Nishie H; Natsume M; Mochizuki H; Hirata Y; Sobue S; Mizushima T; Sano H; Mizuno Y; Nakamura M; Hirano A; Tsuchida K; Adachi K; Seno K; Kitagawa M; Kawai T; Joh T
    Cancer Chemother Pharmacol; 2016 May; 77(5):957-62. PubMed ID: 27002325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness and safety between oxaliplatin-based and cisplatin-based therapy in advanced gastric cancer: A meta-analysis of randomized controlled trials.
    Huang J; Zhao Y; Xu Y; Zhu Y; Huang J; Liu Y; Zhao L; Li Z; Liu H; Wang QL; Qi X
    Oncotarget; 2016 Jun; 7(23):34824-31. PubMed ID: 27166187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Geographic difference in safety and efficacy of systemicchemotherapy for advanced gastric or gastroesophagealcarcinoma: a meta-analysis and meta-regression.
    Hsu C; Shen YC; Cheng CC; Cheng AL; Hu FC; Yeh KH
    Gastric Cancer; 2012 Jul; 15(3):265-80. PubMed ID: 22576708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Doublet Versus Single Agent as Second-Line Treatment for Advanced Gastric Cancer: A Meta-Analysis of 10 Randomized Controlled Trials.
    Zhang Y; Ma B; Huang XT; Li YS; Wang Y; Liu ZL
    Medicine (Baltimore); 2016 Feb; 95(8):e2792. PubMed ID: 26937908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of 5-flurouracil-based neoadjuvant chemotherapy in locally-advanced gastric/gastroesophageal cancer: a meta-analysis.
    Ge L; Wang HJ; Yin D; Lei C; Zhu JF; Cai XH; Zhang GQ
    World J Gastroenterol; 2012 Dec; 18(48):7384-93. PubMed ID: 23326149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical Trial.
    Rugo HS; Barve A; Waller CF; Hernandez-Bronchud M; Herson J; Yuan J; Sharma R; Baczkowski M; Kothekar M; Loganathan S; Manikhas A; Bondarenko I; Mukhametshina G; Nemsadze G; Parra JD; Abesamis-Tiambeng ML; Baramidze K; Akewanlop C; Vynnychenko I; Sriuranpong V; Mamillapalli G; Ray S; Yanez Ruiz EP; Pennella E;
    JAMA; 2017 Jan; 317(1):37-47. PubMed ID: 27918780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of trastuzumab beyond progression in HER2 positive advanced gastric cancer: a multicenter prospective observational cohort study.
    Li Q; Jiang H; Li H; Xu R; Shen L; Yu Y; Wang Y; Cui Y; Li W; Yu S; Liu T
    Oncotarget; 2016 Aug; 7(31):50656-50665. PubMed ID: 27409420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose capecitabine plus trastuzumab as first-line treatment in patients 75 years of age or older with HER2-positive advanced gastric cancer: a pilot study.
    Kim YS; Sym SJ; Baek MY; Park I; Hong J; Ahn HK; Park J; Cho EK; Lee WK; Chung M; Kim HS; Lee JH; Shin DB
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1267-72. PubMed ID: 26482716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study.
    Meulendijks D; Beerepoot LV; Boot H; de Groot JW; Los M; Boers JE; Vanhoutvin SA; Polee MB; Beeker A; Portielje JE; de Jong RS; Goey SH; Kuiper M; Sikorska K; Beijnen JH; Tesselaar ME; Schellens JH; Cats A
    Invest New Drugs; 2016 Feb; 34(1):119-28. PubMed ID: 26643663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of ramucirumab in gastric or gastroesophageal cancer: A systematic review and meta-analysis.
    Wu R; Yuan S; Wang Y; Nan Y; Chen Z; Yuan H; Wang Z; Li Z; Zong D
    Clin Res Hepatol Gastroenterol; 2024 Oct; 48(8):102466. PubMed ID: 39299442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of targeted therapy with or without chemotherapy in advanced gastric cancer treatment: a network meta-analysis of well-designed randomized controlled trials.
    Zhao TT; Xu H; Xu HM; Wang ZN; Xu YY; Song YX; Yin SC; Liu XY; Miao ZF
    Gastric Cancer; 2018 May; 21(3):361-371. PubMed ID: 29455269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value of serum HER2 ECD in patients with HER2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy.
    Zhou J; Peng Z; Liu Y; Gong J; Zhang X; Lu M; Gao J; Li Y; Li Y; Shen L
    J Gastroenterol; 2015 Sep; 50(9):955-61. PubMed ID: 25702260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane- and trastuzumab-naïve patients with HER2-positive, previously treated, advanced, or recurrent gastric cancer (JFMC45-1102).
    Nishikawa K; Takahashi T; Takaishi H; Miki A; Noshiro H; Yoshikawa T; Nishida Y; Iwasa S; Miwa H; Masuishi T; Boku N; Yamada Y; Kodera Y; Yoshida K; Morita S; Sakamoto J; Saji S; Kitagawa Y
    Int J Cancer; 2017 Jan; 140(1):188-196. PubMed ID: 27521503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer.
    Farhat F; Kattan JG; Ghosn M
    Cancer Chemother Pharmacol; 2016 May; 77(5):1069-77. PubMed ID: 27059339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.